# SMIM6

## Overview
SMIM6 is a gene that encodes the small integral membrane protein 6, which is categorized as a transmembrane protein. This protein is involved in various cellular processes, although its specific functions are not yet fully understood. Research has indicated that SMIM6 may play a role in the regulation of gene expression and cellular signaling pathways, potentially impacting disease progression in certain conditions. The gene's expression levels have been associated with diseases such as Type 2 Diabetes and various cancers, suggesting its potential as a biomarker for these conditions (Weng2023Single; Zhang2022Characterizing; Vastrad2020Screening). Further studies are required to fully elucidate the biological functions and clinical significance of SMIM6 and its encoded protein.

## Clinical Significance
The SMIM6 gene has been implicated in various diseases and conditions through alterations in its expression levels. In the context of Type 2 Diabetes (T2D), SMIM6 is downregulated, which is associated with β-cell heterogeneity. This downregulation is linked to the loss of accessibility of HNF1A motifs in promoter or enhancer regions, suggesting a role in the disease's progression (Weng2023Single).

In bladder urothelial carcinoma, SMIM6 is significantly upregulated, with a log fold change of 2.966013 and a p-value of 0.005872, indicating its potential involvement in cancer progression. This upregulation suggests that SMIM6 may serve as a biomarker for this type of cancer, although the specific clinical implications of this expression change are not fully detailed (Vastrad2020Screening).

In esophageal adenocarcinoma, SMIM6 is noted for isoform switching events without differential gene expression, which may have functional consequences independent of overall gene expression changes. However, the clinical significance of these isoform changes in SMIM6 remains unclear (Zhang2022Characterizing). Further research is needed to elucidate the precise role of SMIM6 in these conditions.


## References


[1. (Weng2023Single) Chen Weng, Anniya Gu, Shanshan Zhang, Leina Lu, Luxin Ke, Peidong Gao, Xiaoxiao Liu, Yuntong Wang, Peinan Hu, Dylan Plummer, Elise MacDonald, Saixian Zhang, Jiajia Xi, Sisi Lai, Konstantin Leskov, Kyle Yuan, Fulai Jin, and Yan Li. Single cell multiomic analysis reveals diabetes-associated β-cell heterogeneity driven by hnf1a. Nature Communications, September 2023. URL: http://dx.doi.org/10.1038/s41467-023-41228-3, doi:10.1038/s41467-023-41228-3. This article has 10 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-023-41228-3)

[2. (Zhang2022Characterizing) Yun Zhang, Katherine M. Weh, Connor L. Howard, Jean-Jack Riethoven, Jennifer L. Clarke, Kiran H. Lagisetty, Jules Lin, Rishindra M. Reddy, Andrew C. Chang, David G. Beer, and Laura A. Kresty. Characterizing isoform switching events in esophageal adenocarcinoma. Molecular Therapy - Nucleic Acids, 29:749–768, September 2022. URL: http://dx.doi.org/10.1016/j.omtn.2022.08.018, doi:10.1016/j.omtn.2022.08.018. This article has 9 citations.](https://doi.org/10.1016/j.omtn.2022.08.018)

[3. (Vastrad2020Screening) Basavaraj Vastrad and Chanabasayya Vastrad. Screening and identification of potential prognostic biomarkers in bladder urothelial carcinoma: evidence from bioinformatics analysis. Gene Reports, 20:100658, September 2020. URL: http://dx.doi.org/10.1016/j.genrep.2020.100658, doi:10.1016/j.genrep.2020.100658. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.genrep.2020.100658)